90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-hodgkin lymphoma: Updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1977-1983

  Morschhauser, Franck ^a   Radford, John ^e   Van Hoof, Achiel ^g   Botto, Barbara ^h   Rohatiner, Ama Z S ^f   Salles, Gilles ^b   Soubeyran, Pierre ^c   Tilly, Herve ^d   Bischof Delaloye, Angelika ⁱ   Van Putten, Wim L J ^j   Kylstra, Jelle W ^l   Hagenbeek, Anton ^k  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g General Hospital St Jan   (Belgium)

^h Dermatopathology Section Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j For the Dutch Belgian Hemato Oncology Cooperative Group (HOVON) Erasmus   (Netherlands)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l Spectrum Pharmaceuticals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE PLUS DOXORUBICIN PLUS PREDNISOLONE PLUS RITUXIMAB PLUS VINCRISTINE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; OXALIPLATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; YTTRIUM;

ACUTE MYELOID LEUKEMIA; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BASAL CELL CARCINOMA; BOWEN DISEASE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARCINOMA; COLON CANCER; CONGENITAL MALFORMATION; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE DIFFERENTIATED ADENOCARCINOMA; LIP CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SECOND CANCER; SINGLE DRUG DOSE; SPINOCELLULAR CARCINOMA; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; SQUAMOUS CELL SKIN CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THYROID PAPILLARY CARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; INTERNATIONAL COOPERATION; KAPLAN MEIER METHOD; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RADIOIMMUNOTHERAPY; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

MLCS; MLOWN;

EID: 84880657268     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.6400     Document Type: Article

References (22)

1. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphoma, Version 2, 2011. http://www nccn org/professionals/physician_gls/f_guidelines asp
2. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER): SEER Cancer Statistics, SEER Stat Fact Sheets: Lymphoma. http://seer.cancer.gov/statfacts/html/lymph.html
3. Seiler TM, Hiddemann W: Advances in the management of follicular lymphoma. Curr Opin Oncol 24:742-747, 2012
4. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
5. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447-8452, 2005
6. Schulz H, Bohlius J, Skoetz N, et al: Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev 4:CD003805, 2007
7. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002
8. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20() B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17: 3793-3803, 1999
9. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262-3269, 2002
10. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20: 2453-2463, 2002
11. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
12. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
14. Pedersen-Bjergaard J, Andersen MK, Andersen MT, et al: Genetics of therapy-related myelodys-plasia and acute myeloid leukemia. Leukemia 22: 240-248, 2008
15. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614, 2009
16. Bachy E, Houot R, Morschhauser F, et al: Eight-year follow-up of the GELA-GOELAMS FL200 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma patients. Ann Oncol 22:iv88-iv89, 2011 (suppl 4; abstr 021)
17. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
18. Burnette BL, Wiseman G, Habermann TM, et al: Risk of transformation of follicular lymphoma to high grade lymphoma after radioimmunotherapy: A prospective observational single institutional experience. Blood 18, 2011 (abstr 1572)
19. Press OW, Unger JM, Rimsza LM, et al: A phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: SWOG S0016. J Clin Oncol 31:314-320, 2013
20. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2010
21. Czuczman MS, Emmanouilides C, Darif M, et al: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25:4285-4292, 2007
22. 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (Mab-Thera). Bethesda, MD, National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00662948